Sapien Valve Reimbursement Begins Taking Shape, But Key Questions Remain
Edwards Lifescience’s proactive reimbursement strategy for its market-pending Sapien transcatheter aortic valve appears to be progressing as planned, but questions remain about how Medicare coverage policies could ultimately affect adoption of the closely- watched technology.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
